Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Rituximab for Prevention of cGvHD
NCT00186628Phase 2Completed
- Sponsor
- Stanford University
- Start
- Jun 2005
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Stanford University. Primary endpoint: Chronic Graft-vs-Host Disease at 4 years. Started Jun 2005; status: completed.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00186628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00186628.